Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
MediSpectra: Proceeds from a $13 mil. round of financing will be used to support a pivotal randomized, controlled clinical study enrolling 2,000 women to evaluate its Luma cervical imaging device. The Series F preferred rights financing, announced Aug. 21, was led by AIG Global Investment Corp. and raises the privately held, Lexington, Massachusetts firm's total venture capital funding to $56 mil. The Luma system combines fluorescence and white light to completely scan the cervix in 12 seconds and project it onto a monitor, MediSpectra says. "Our initial goal is to use the Luma system in combination with the colposcope, thereby improving the detection of high-grade pre-cancerous disease," CEO Robert Anacone notes...